Founded by Darcy Tocci
Neuro11 Therapeutics is a pioneering biotechnology company focused on unlocking the epigenetic frontier in central nervous system (CNS) disorders. With a deep commitment to scientific innovation and clinical impact, we are developing first-in-class HDAC11 inhibitors to treat neurodegenerative diseases like Alzheimer’s. Our lead candidate, PB151, is a brain-penetrant, selective, and orally bioavailable compound engineered to precisely modulate gene expression without the off-target toxicity of broad-spectrum HDAC inhibitors. By targeting neuroinflammation and epigenetic dysregulation, we aim to address the critical unmet need for safe, effective CNS therapies.
At Neuro11, our mission is to transform the treatment landscape for CNS disorders by delivering precision-targeted, epigenetic-based therapies. We are driven by the belief that a deeper understanding of gene regulation and inflammation in the brain can unlock curative possibilities for conditions like Alzheimer’s, Parkinson’s, and chronic pain. Our approach combines cutting-edge science, rigorous validation, and a commitment to translational impact to develop therapies that are not only effective but also accessible and well-tolerated
The Neuro11 team is composed of seasoned leaders and scientific pioneers at the forefront of epigenetics and neuroscience. Co-founded by Darcy Tocci, MBA, who leads the company as CEO, and academic visionaries Dr. Changning Wang and Dr. Martin (Can) Zhang, our leadership brings a powerful blend of entrepreneurial and scientific acumen. We are also guided by Dr. Rudolph E. Tanzi, a renowned neuroscientist and scientific advisor, whose insights into Alzheimer’s disease significantly shape our development strategy. Recently joined by Dr. Yueyang Zhang, a talented researcher with a strong background in molecular neuroscience, our team continues to grow in strength and capability as we work to revolutionize CNS drug development.
Neuro11 is advancing with a clear roadmap to clinical entry. In the near term, we aim to finalize candidate selection, complete IND-enabling studies, and submit our investigational new drug (IND) application to begin Phase 1 trials. Our long-term vision includes expanding our HDAC11 inhibitor platform into other indications such as Parkinson’s disease, chronic pain, and oncology. With scalable technology, strong IP, and a differentiated mechanism of action, we are poised to lead a new era of precision CNS therapeutics.
Reach out. Please reach out. We need you to reach out.
darcy@darcytocci.com